🚀 VC round data is live in beta, check it out!
BioXcel Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for BioXcel Therapeutics and similar public comparables like Marinomed Biotech, Marker Therapeutics, Intervacc, Elicera Therapeutics and more.
BioXcel Therapeutics Overview
About BioXcel Therapeutics
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company’s commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Founded
2017
HQ
Employees
37
Website
Sectors
Financials (LTM)
EV
$110M
BioXcel Therapeutics Financials
BioXcel Therapeutics reported last 12-month revenue of $879K and negative EBITDA of ($50M).
In the same LTM period, BioXcel Therapeutics generated $651K in gross profit, ($50M) in EBITDA losses, and had net loss of ($67M).
Revenue (LTM)
BioXcel Therapeutics P&L
In the most recent fiscal year, BioXcel Therapeutics reported revenue of $642K and EBITDA of ($50M).
BioXcel Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $879K | XXX | $642K | XXX | XXX | XXX |
| Gross Profit | $651K | XXX | $478K | XXX | XXX | XXX |
| Gross Margin | 74% | XXX | 74% | XXX | XXX | XXX |
| EBITDA | ($50M) | XXX | ($50M) | XXX | XXX | XXX |
| EBITDA Margin | (5655%) | XXX | (7819%) | XXX | XXX | XXX |
| EBIT Margin | (5423%) | XXX | (7830%) | XXX | XXX | XXX |
| Net Profit | ($67M) | XXX | ($70M) | XXX | XXX | XXX |
| Net Margin | (7587%) | XXX | (10887%) | XXX | XXX | XXX |
| Net Debt | — | — | $81M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
BioXcel Therapeutics Stock Performance
BioXcel Therapeutics has current market cap of $29M, and enterprise value of $110M.
Market Cap Evolution
BioXcel Therapeutics' stock price is $1.08.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $110M | $29M | -0.5% | XXX | XXX | XXX | $-2.58 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBioXcel Therapeutics Valuation Multiples
BioXcel Therapeutics trades at 125.7x EV/Revenue multiple, and (2.2x) EV/EBITDA.
EV / Revenue (LTM)
BioXcel Therapeutics Financial Valuation Multiples
As of April 11, 2026, BioXcel Therapeutics has market cap of $29M and EV of $110M.
Equity research analysts estimate BioXcel Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
BioXcel Therapeutics has a P/E ratio of (0.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $29M | XXX | $29M | XXX | XXX | XXX |
| EV (current) | $110M | XXX | $110M | XXX | XXX | XXX |
| EV/Revenue | 125.7x | XXX | 172.1x | XXX | XXX | XXX |
| EV/EBITDA | (2.2x) | XXX | (2.2x) | XXX | XXX | XXX |
| EV/EBIT | (2.3x) | XXX | (2.2x) | XXX | XXX | XXX |
| EV/Gross Profit | 169.6x | XXX | 231.1x | XXX | XXX | XXX |
| P/E | (0.4x) | XXX | (0.4x) | XXX | XXX | XXX |
| EV/FCF | (1.9x) | XXX | (1.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified BioXcel Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
BioXcel Therapeutics Margins & Growth Rates
BioXcel Therapeutics' revenue in the last 12 month grew by 614%.
BioXcel Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.4M for the same period.
BioXcel Therapeutics' rule of 40 is (3076%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
BioXcel Therapeutics' rule of X is (2874%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
BioXcel Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 614% | XXX | 135% | XXX | XXX | XXX |
| EBITDA Margin | (5655%) | XXX | (7819%) | XXX | XXX | XXX |
| EBITDA Growth | 7% | XXX | (4%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (3076%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (2874%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 63% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 3129% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 2984% | XXX | 4716% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 7904% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
BioXcel Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Marinomed Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Marker Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Intervacc | XXX | XXX | XXX | XXX | XXX | XXX |
| Elicera Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cue Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BioXcel Therapeutics M&A Activity
BioXcel Therapeutics acquired XXX companies to date.
Last acquisition by BioXcel Therapeutics was on XXXXXXXX, XXXXX. BioXcel Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by BioXcel Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBioXcel Therapeutics Investment Activity
BioXcel Therapeutics invested in XXX companies to date.
BioXcel Therapeutics made its latest investment on XXXXXXXX, XXXXX. BioXcel Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by BioXcel Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout BioXcel Therapeutics
| When was BioXcel Therapeutics founded? | BioXcel Therapeutics was founded in 2017. |
| Where is BioXcel Therapeutics headquartered? | BioXcel Therapeutics is headquartered in United States. |
| How many employees does BioXcel Therapeutics have? | As of today, BioXcel Therapeutics has over 37 employees. |
| Who is the CEO of BioXcel Therapeutics? | BioXcel Therapeutics' CEO is Vimal Mehta. |
| Is BioXcel Therapeutics publicly listed? | Yes, BioXcel Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of BioXcel Therapeutics? | BioXcel Therapeutics trades under BTAI ticker. |
| When did BioXcel Therapeutics go public? | BioXcel Therapeutics went public in 2018. |
| Who are competitors of BioXcel Therapeutics? | BioXcel Therapeutics main competitors are Marinomed Biotech, Marker Therapeutics, Intervacc, Elicera Therapeutics. |
| What is the current market cap of BioXcel Therapeutics? | BioXcel Therapeutics' current market cap is $29M. |
| What is the current revenue of BioXcel Therapeutics? | BioXcel Therapeutics' last 12 months revenue is $879K. |
| What is the current revenue growth of BioXcel Therapeutics? | BioXcel Therapeutics revenue growth (NTM/LTM) is 614%. |
| What is the current EV/Revenue multiple of BioXcel Therapeutics? | Current revenue multiple of BioXcel Therapeutics is 125.7x. |
| Is BioXcel Therapeutics profitable? | No, BioXcel Therapeutics is not profitable. |
| What is the current EBITDA of BioXcel Therapeutics? | BioXcel Therapeutics has negative EBITDA and is not profitable. |
| What is BioXcel Therapeutics' EBITDA margin? | BioXcel Therapeutics' last 12 months EBITDA margin is (5655%). |
| What is the current EV/EBITDA multiple of BioXcel Therapeutics? | Current EBITDA multiple of BioXcel Therapeutics is (2.2x). |
| What is the current FCF of BioXcel Therapeutics? | BioXcel Therapeutics' last 12 months FCF is ($57M). |
| What is BioXcel Therapeutics' FCF margin? | BioXcel Therapeutics' last 12 months FCF margin is (6493%). |
| What is the current EV/FCF multiple of BioXcel Therapeutics? | Current FCF multiple of BioXcel Therapeutics is (1.9x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.